Novartis med gets nod for fracture prevention

SPOTLIGHT: Novartis med gets nod for fracture prevention
Novartis said the FDA approved its bone-building drug Reclast as a treatment to prevent additional fractures following a hip fracture; the once-yearly drug's revised label includes data showing a 35 percent reduction in follow-up fractures. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.